当前位置：药药网 / 药品 / 美国NDC复合药物数据库文件(本栏目更新到2026-3-31)
药品名称： 商品名称： 药品NDC： 报告期内： -格式:2020-5-3
NDC包装id： 市场分类： 活性成分： 持证企业：
 美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)
药品名称(分析)
商品名
药品NDC
专利人(分析)
报告期内
活性成分
市场分类
规格(分析)
NDC包装id
031087 MINOXIDIL 7% / PROGESTERONE 0.1% / TRETINOIN 0.025%
HUMAN COMPOUNDED DRUG
72934-4354
SKNV
2024-2
TRETINOIN; MINOXIDIL; PROGESTERONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.025 g/100 mL; 7 g/100 mL; .1 g/100 mL
72934-4354-8
141024 HYDROCORTISONE 0.5% / HYDROQUINONE 6% / TRETINOIN 0.05%
HUMAN COMPOUNDED DRUG
72934-6377
SKNV
2024-2
HYDROCORTISONE; HYDROQUINONE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.5 g/100 mL; 6 g/100 mL; .05 g/100 mL
72934-6377-2
141061 HYDROCORTISONE 0.5% / HYDROQUINONE 8% / TRETINOIN 0.025%
HUMAN COMPOUNDED DRUG
72934-6387
SKNV
2024-2
HYDROQUINONE; HYDROCORTISONE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
8 g/100 mL; .5 g/100 mL; .025 g/100 mL
72934-6387-2
011009 NIACINAMIDE 4% / TRETINOIN 0.05%
HUMAN COMPOUNDED DRUG
72934-2299
SKNV
2024-1
NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
4 g/100 mL; .05 g/100 mL
72934-2299-4
011020 NIACINAMIDE 4% / TRETINOIN 0.05%
HUMAN COMPOUNDED DRUG
72934-1304
SKNV
2024-1
NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
4 g/100 mL; .05 g/100 mL
72934-1304-2
011013 NIACINAMIDE 4% / TRETINOIN 0.025%
HUMAN COMPOUNDED DRUG
72934-2300
SKNV
2024-1
NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
4 g/100 mL; .025 g/100 mL
72934-2300-2
011021 NIACINAMIDE 4% / TRETINOIN 0.05%
HUMAN COMPOUNDED DRUG
72934-2304
SKNV
2024-1
NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
4 g/100 mL; .05 g/100 mL
72934-2304-2
011031 NIACINAMIDE 4% / TRETINOIN 0.1%
HUMAN COMPOUNDED DRUG
72934-2306
SKNV
2024-1
NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
4 g/100 mL; .1 g/100 mL
72934-2306-2
011035 NIACINAMIDE 4% / TRETINOIN 0.1%
HUMAN COMPOUNDED DRUG
72934-2309
SKNV
2024-1
NIACINAMIDE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
4 g/100 mL; .1 g/100 mL
72934-2309-2
Ropivacaine HCl
HUMAN COMPOUNDED DRUG
73013-4009
OurPharma LLC
2023-2
ROPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5 mg/1 mL
73013-4009-3
Bupivacaine HCl
HUMAN COMPOUNDED DRUG
73013-4004
OurPharma LLC
2023-2
BUPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1 mg/1 mL
73013-4004-1
Ketamine HCl
HUMAN COMPOUNDED DRUG
73013-2016
OurPharma LLC
2023-2
KETAMINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5 mg/1 mL
73013-2016-1
fentanyl citrate, ropivacaine hydrochloride
HUMAN COMPOUNDED DRUG
73013-1050
OurPharma LLC
2023-2
FENTANYL CITRATE; ROPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 ug/1 mL; 1 mg/1 mL
73013-1050-1
Ketamine HCl
HUMAN COMPOUNDED DRUG
73013-2012
OurPharma LLC
2023-2
KETAMINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 mg/1 mL
73013-2012-1
Bupivacaine HCl
HUMAN COMPOUNDED DRUG
73013-4005
OurPharma LLC
2023-2
BUPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1.25 mg/1 mL
73013-4005-2
Ropivacaine HCl
HUMAN COMPOUNDED DRUG
73013-4002
OurPharma LLC
2023-2
ROPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 mg/1 mL
73013-4002-2
Ropivacaine HCl
HUMAN COMPOUNDED DRUG
73013-4002
OurPharma LLC
2023-2
ROPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 mg/1 mL
73013-4002-1
fentanyl citrate, ropivacaine hydrochloride
HUMAN COMPOUNDED DRUG
73013-1053
OurPharma LLC
2023-2
FENTANYL CITRATE; ROPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 ug/1 mL; 2 mg/1 mL
73013-1053-1
Fentanyl Drip 2500 mcg in 50 mL
HUMAN COMPOUNDED DRUG
83863-6030
Park Avenue Compounding
2024-2
FENTANYL CITRATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.05 mg/1 mL
83863-6030-1
Neostigmine Methylsulfate 5 mg in 5 mL (1mg/mL)
HUMAN COMPOUNDED DRUG
83863-0329
Park Avenue Compounding
2024-2
NEOSTIGMINE METHYLSULFATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1 mg/1 mL
83863-0329-1
网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3